Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pseudosemiglabrin is a natural prenylated flavone isolated from the aerial parts of *Tephrosia* species, including *Tephrosia apollinea*, *Tephrosia semiglabra*, and *Tephrosia purpurea*. It has been investigated preclinically for its potential therapeutic applications in oncology, inflammatory diseases, epilepsy, and acute pancreatitis. In breast cancer models, pseudosemiglabrin exhibits chemopreventive and antiangiogenic properties by inhibiting VEGF expression, VEGFR phosphorylation, and the Notch pathway, as well as acting as an inhibitor of aromatase and the estrogen receptor. Additionally, it has demonstrated anti-inflammatory effects through selective COX-2 inhibition and reduction of pro-inflammatory cytokines (TNF-alpha, IL-1beta), and neuroprotective/anti-epileptic properties by modulating GABAergic and glutamatergic neurotransmission.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pseudosemiglabrin.